Drug Search Results
More Filters [+]

Piboserod

Alternative Names: piboserod, sb-207266
Latest Update: 2023-11-09
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: 5-HT4 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Piboserod

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Heart Failure|Atrial Fibrillation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2005-004487-22

P2

Completed

Heart Failure

2007-07-17

NCT00041496

P2

Completed

Atrial Fibrillation

2003-12-01

BMI 001 / SMR-1389

P2

Completed

Heart Failure

None

Recent News Events